Effects of Atropine 0.01% on Refractive Errors in Children with Myopia.

Xingxue Zhu,Yuliang Wang,Yujia Liu,Chaoying Ye,Xingtao Zhou,Xiaomei Qu

DOI: https://doi.org/10.1016/j.heliyon.2023.e18743

IF: 3.776

2023-01-01

Heliyon

Abstract:Background: Little is known about changes in astigmatism during atropine treatment. We aimed to explore the effects of atropine 0.01% eye drops on both spherical and cylindrical refractive errors in myopic children. Methods: Children aged 6-14 years with myopia & GE;-6.00 D and <-0.50 D, and total astigmatism >-2.00 D in at least one eye were enrolled. Subjects were randomised either to receive atropine 0.01% once nightly with single-vision lenses or simply to wear single-vision lenses and were followed up at 3-month intervals. Cycloplegic refraction and axial length were measured. The magnitude and direction of total astigmatism (TA), corneal astigmatism (CA), and residual astigmatism (RA) were evaluated. Results: Overall, 119 eyes (69 eyes in the atropine group and 50 eyes in the control group) were included in the final analyses after 9 months. Atropine-treated eyes showed significantly less progression of myopia than did control eyes (spherical equivalent:-0.35 & PLUSMN; 0.33 vs.-0.56 & PLUSMN; 0.49 D, p = 0.001; axial length: 0.20 & PLUSMN; 0.19 vs. 0.33 & PLUSMN; 0.19 mm, p < 0.001). Compared with control eyes (-0.04 & PLUSMN; 0.23 D), a significant increase in TA was observed in the atropine-treated eyes (-0.14 & PLUSMN; 0.29 D); this was mainly attributed to the increase in CA (-0.17 & PLUSMN; 0.26 D) rather than the minor decrease in RA (0.02 & PLUSMN; 0.32 D). Conclusions: Atropine 0.01% was effective in preventing myopia progression, whereas 9 months of atropine treatment resulted in a clinically small, but statistically significant increase in TA in myopic Chinese children.